Fig. 3: Clinical utility of the COMB-Radscore. | British Journal of Cancer

Fig. 3: Clinical utility of the COMB-Radscore.

From: Intratumoral and peritumoral PET/CT-based radiomics for non-invasively and dynamically predicting immunotherapy response in NSCLC

Fig. 3

Kaplan-Meier analysis of PFS (a) and OS (b) for the low and high COMB-Radscore groups in the training (left) and testing (right) cohorts. c Proportional composition of different patient responses between the low and high COMB-Radscore groups in the training (left) and testing (right) cohorts. HR hazard ratio, CI confidence interval, PFS progression-free survival, OS overall survival, CR complete response, PR partial response, SD stable disease, PD progressive disease. The definitions of CR, PR, SD, and PD were based on the RECIST V.1.1 criteria.

Back to article page